Clinical trials: Overactive Bladder (OAB)
Overactive Bladder (OAB), Lower Urinary Tract Dysfunction
Parasacral TENS Project
The purpose of the project is to compare the efficacy of parasacral transcutaneous electric nerve stimulation (TENS) versus standard second-line therapy (oral anticholinergics) for pediatric patients with overactive bladder (OAB)…
- Trial name
- NCT07892417
- Testing
- Parasacral transcutaneous electric nerve stimulation (TENS), Oxybutynin
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Overactive Bladder (OAB), Menopause
Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder
The goal of this Pre-Post Quasi-experimental study is to investigates the effect of vaginal estrogen therapy on changes in the urinary microbiome and its association with improvement in overactive bladder (OAB) symptoms in…
- Conditions
- Overactive Bladder (OAB), Menopause, Microbiome
- Trial name
- NCT06780163
- Testing
- 17β-estradiol 10 mcg
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Overactive Bladder (OAB), Transcutaneous Neurostimulation
Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine vs. Transcutaneous Neurostimulation
The absence of infectious, urological and neurological causes defines the idiopathic character of overactive bladder (OAB). Although a progressive approach starting with behavioural therapy (urotherapy) is recommended…
- Conditions
- Overactive Bladder (OAB), Transcutaneous Neurostimulation, Posterior Tibial Nerve Stimulation
- Trial name
- HAV-O-TENS (NCT07030803)
- Testing
- Oxybutynin, medical device Urostim
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Overactive Bladder (OAB), Drug Delivery Systems
Transdermal Versus Oral Oxybutynin in Pediatric OAB
This is a prospective, randomized controlled clinical trial designed to compare the efficacy and safety of transdermal versus oral oxybutynin in children diagnosed with overactive bladder (OAB) who remain symptomatic despite…
- Conditions
- Overactive Bladder (OAB), Drug Delivery Systems, Anticholinergic Side Effects, Children and Adolescents, Boys and Girls
- Trial name
- NCT07081906
- Testing
- Oral Oxybutynin, transdermal oxybutinin
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Overactive Bladder (OAB)
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder
In this study, the investigators aim to evaluate the role of urinary ATP as a biomarker for the diagnosis, treatment, and follow-up of OAB in children for the first time in a clinical investigation, as previous research has been…
- Trial name
- NCT06785558
- Testing
- Anticholinergic therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Marmara University
Overactive Bladder (OAB)
Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder
Overactive bladder (OAB) is a syndrome characterized by urinary urgency, often accompanied by frequency and nocturia, with or without urge incontinence, without urinary tract infection or other clear pathological changes.
- Trial name
- NCT06765629
- Testing
- Non-invasive Percutaneous Tibial Nerve Stimulation (TTNS) group
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.